-
FDA confirms response date for Type C Meeting as 29th August 2022
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), has advised that it has now received Type C Meeting confirmation from the Food and Drug Administration (“FDA”). The statement of purpose, objectives, and proposed agenda of the Type C meeting…
-
Notice of AGM & Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2021 will be posted to shareholders on 6 June 2022. These documents will be available shortly, in electronic…
-
FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the “Period”). Key Highlights (including post Period review) Loss for the Period of £8.2m (£6.9m at 31 December 2020) Research and development expenses of £3.7m (31 December 2020: £2.4m)…
-
UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that final preparations are now underway to progress Lupuzor™ into its new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Further to the recent positive results from the Lupuzor™/P140 Pharmacokinetic (“PK”) study announced on 13 April 2022, we are…
-
UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study.
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide positive data from the Lupuzor™/P140 pharmacokinetic (“PK”) study, required by the US Food & Drug Administration (”FDA”), as part of the new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Key highlights Data successfully demonstrates the PK study has…
-
LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide an update on the Lupuzor™ pharmacokinetic (“PK”) study, as part of the new optimised international Phase 3 trial of Lupuzor™ in Lupus patients. Key highlights Medical and Health Products Regulatory Agency (“MHRA”) approves commencement of the PK study Volunteers have been…
-
TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022)
TR-1: Standard form for notification of major holdings To view notification click here
-
TR1 – Luca Associates – Major Holdings in Shares (4 January 2022)
TR-1: Standard form for notification of major holdings To view notification click here
-
TR1 – Lanstead – Major Holding in Shares
TR-1: Standard form for notification of major holdings To view notification click here
